The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using $^{18}$F-AV45: Is Amyloid the Principal Actor in the Disease?

Emilie Beaufils$^a$  Maria Joao Ribeiro$^{a, b}$  Emilie Vierron$^c$
Johnny Vercouillie$^b$  Diane Dufour-Rainfray$^{a, b}$  Jean-Philippe Cottier$^{a, b}$
Vincent Camus$^{a, b}$  Karl Mondon$^{a, b}$  Denis Guilloteau$^{a, b}$
Caroline Hommet$^{a, b}$

$^a$CHRU Bretonneau, $^b$INSERM U930, Imagerie et Cerveau, Université François Rabelais de Tours, and $^c$CIC-IT INSERM 0806, Tours, France

Key Words
Biomarker · Posterior cortical atrophy · Alzheimer’s disease · Positron emission tomography · Amyloid

Abstract

Background: Posterior cortical atrophy (PCA) is characterized by progressive higher-order visuoperceptual dysfunction and praxis declines. This syndrome is related to a number of underlying diseases, including, in most cases, Alzheimer’s disease (AD). The aim of this study was to compare the amyloid load with $^{18}$F-AV45 positron emission tomography (PET) between PCA and AD subjects. Methods: We performed $^{18}$F-AV45 PET, cerebrospinal fluid (CSF) biomarker analysis and a neuropsychological assessment in 11 PCA patients and 12 AD patients. Results: The global and regional $^{18}$F–AV45 uptake was similar in the PCA and AD groups. No significant correlation was observed between global $^{18}$F–AV45 uptake and CSF biomarkers or between regional $^{18}$F–AV45 uptake and cognitive and affective symptoms. Conclusion: This $^{18}$F–AV45 PET amyloid imaging study showed no specific regional pattern of cortical $^{18}$F–AV45 binding in PCA patients. These results confirm that a distinct clinical phenotype in amnestic AD and PCA is not related to amyloid distribution.

Introduction

Posterior cortical atrophy (PCA) is a syndrome characterized by a progressive decline in higher-order visuospatial function, associated with a decline in praxis, although memory and insight are relatively spared [1, 2]. In this kind of clinical presentation with progressive
cognitive alteration, neuroimaging studies usually show focal atrophy and/or hypoperfusion in the posterior regions of the brain [3].

While the clinical presentation is dominated by higher-order visuospatial dysfunction, neuropathological studies report that PCA is typically associated with underlying Alzheimer’s disease (AD) [4, 5]. Less frequently, this clinical presentation has been shown to be associated with corticobasal degeneration diseases, Creutzfeldt-Jakob disease, dementia with Lewy bodies, or subcortical gliosis [6].

The core neuropsychological features of PCA are Balint’s syndrome, Gerstmann’s syndrome, alexia, visual object agnosia, visuospatial neglect, prosopagnosia, environmental disorientation and apraxia [6]. Associated neurological signs have also been reported, including extrapyramidal motor signs, limb dystonia, visual hallucinations and myoclonus. Early affective symptoms, especially anxiety, are frequently observed [6].

Both chemical and imaging biomarkers are indicators of specific changes that characterize AD in vivo [7]. Consequently, they can help identify the underlying etiology of PCA [8]. Few reports have described cerebrospinal fluid (CSF) biomarker profiles in PCA [9–14]. Most of them fulfilled the biological criteria for typical AD with an increase in the T-tau and p-tau levels and a decrease in the Aβ42 level.

Positron emission tomography (PET) imaging with amyloid probes now offers us the opportunity to investigate brain amyloid deposition in vivo [15]. Among the candidate probes, tracers labelled with carbon 11 have been extensively studied, especially the PIB compound [16]. Few 11C-PIB studies have been conducted in PCA patients [11, 12, 17–24], and the results obtained have been contradictory. Increased 11C-PIB uptake in the occipital cortex has been reported in single cases and small-series studies [12, 17–19], whereas larger-group studies have found no differences in 11C-PIB patterns between PCA and amnestic AD [11, 21, 23] patients. However, the 11C-PIB compound has a radioactive half-life of 20 min, which is a serious limitation for the widespread use of this biomarker for routine clinical purposes.

Fluorine-labelled compounds have a half-life of 110 min, allowing plenty of time for the centralized production and locoregional delivery of the compounds. Several fluorine-18-labelled radioligands have already shown that they can be very useful in AD patients, such as florbetapir (18F-AV45) [25]. This radiotracer has recently been validated as a useful biomarker for distinguishing AD and mild cognitive impairment patients from healthy control subjects [26, 27].

The main aim of this study was to quantify the amyloid load with 18F-AV45 in PCA subjects, with and without associated neurological signs, and then compare the results to AD patients. In addition, we aimed at assessing (1) the correlations between 18F-AV45 uptake and CSF biomarker concentrations and (2) the correlations between 18F-AV45 uptake and cognitive (memory, language, visuocognitive skills and gestural praxis) and affective symptoms in PCA subjects.

**Materials and Methods**

**Subjects**

We recruited PCA patients from the memory clinic in Tours, France. PCA was diagnosed according to the following clinical diagnostic criteria [28]: (1) insidious onset and gradual progression; (2) presentation with visual complaints despite intact primary visual functions; (3) evidence of predominant complex visual disorder on examination; (4) proportionally less impaired memory and verbal fluency, and (5) relatively preserved insight with or without depression.
All PCA patients underwent a thorough neurological and neuropsychological examination. Higher-order visuoperceptual dysfunctions were specifically documented with the Visual Object and Space Perception Battery [29] and the Visual Gnosia Evaluation Protocol [30]. In addition, associated neurological signs and symptoms such as myoclonus and extrapyramidal motor signs were specifically looked for and assessed by the motor subscale of the Unified Parkinson’s Disease Rating Scale. The Mini-Mental State Examination was performed in order to rate global cognitive ability [31]. The neuropsychological battery was designed to assess several cognitive functions including short-term memory and working memory with the Digit Span Subtest [32], verbal episodic memory with the Buschke Selective Reminding Test [33,34], visual memory with the 48-item Delayed Matching-to-Sample task [35], language with naming (DO 80) [36], literacy and semantic fluency [37], writing comprehension and logic and reasoning with the Boston Diagnostic Aphasia Examination [38], visuocognitive skills with the BEC96 figure copy [39], a French neuropsychological battery, and gestural praxis with the Praxis Evaluation Battery [40]. Behavioural and affective symptoms were also assessed using the Neuropsychiatric Inventory Scale [41] and the Hamilton Depression Rating Scale [42].

For diagnostic purposes, all PCA patients underwent structural MRI and brain perfusion with $^{99m}$Tc-ECD or $^{99m}$Tc-HMPAO single-photon emission CT (SPECT), which showed focal atrophy and/or perfusion changes in the posterior brain regions. Lumbar puncture with CSF biomarker analysis was performed for diagnostic purposes several months (16 ± 9 months) before the beginning of the study, according to French health recommendations (HAS 2011). The results had to fulfil the biological criteria for typical AD (defined by T-tau >350 pg/ml, p-tau >60 pg/ml, Aβ 42 <500 pg/ml and/or Aβ 42 /Aβ 40 <0.05) or for atypical AD due to abnormalities of either tau or amyloid protein levels.

Patients with typical AD underwent amyloid PET imaging with $^{18}$F-AV45. The results have been published in a previous study performed in the memory clinic in Tours [27]. AD patients met the NINCDS-ADRDA criteria for probable AD dementia [43]. Unlike for PCA subjects, lumbar puncture to analyse CSF biomarkers was not conducted for diagnostic purposes in all AD subjects, but only in the youngest ones, in accordance with the French health recommendations.

In order to meet French regulations and laws on biomedical research, the study was approved by the Local Ethics Committee in Tours and the French Agency for Safety and Security for Medical Devices.

$^{18}$F-AV45 PET Imaging

$^{18}$F-AV45 was prepared by nucleophilic substitution of a tosylate precursor (E)-2-(2-(2-(5-(4-(tert-butoxycarbonyl(methyl) amino)styril)pyridin-2-yl oxy)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate provided by Avid Radiopharmaceuticals, Inc. (Philadelphia, Pa., USA) on an automatic synthesizer, according to the method already described in the literature [44]. The radiochemical purity and specific activity were approximately 98% and 180 ± 70 GBq/μmol (mean ± SD values of 20 experiments). The radiochemical yields were 40–45%. Subjects were examined using whole-body hybrid PET-CT scanners: a Dual Gemini (Philips Medical Systems) and a Discovery RX VCT 64 (General Electric). All the acquisitions were performed in the 3D detection mode. Acquisition data were processed by adapting the reconstruction parameters to those of the tomograph having the lowest spatial resolution (Dual Philips Gemini) so that the images could be matched. All PET sinograms were reconstructed with an iterative 3D algorithm, with corrections for random, scatter, photon attenuation and decay into images with an isotropic voxel size of $2 \times 2 \times 2$ mm$^3$ and a spatial resolution of approximately 5 mm full width at half maximum at the centre of the field of view. Acquisition data were processed with the standard package delivered with each acquisition system. All
Cerebral emission scans were started 50 min after $^{18}$F-AV45 injection. The mean ± SD injected radioactivity was 237 ± 51 MBq. For each subject, two frames of 10 min were acquired but only the first one was analysed qualitatively and quantitatively.

**Image Analysis**

The $^{18}$F-AV45 PET images were co-registered to the $^{18}$F-AV45 template, proposed by Wong et al. [45], in the Talairach space by PMOD® version 3.2 (PMOD Technologies) using a mutual-information similarity function. Standardized uptake values were obtained by normalizing tissue concentrations to the injected dose and patient body weight. Regions of interest were defined in several cerebral regions (precuneus, anterior cingulate, posterior cingulate, frontal, temporal, parietal and occipital) according to the MNI-AAL atlas. Cortical-to-cerebellum standardized uptake value ratios were calculated and used for intersubject comparison, since the cerebellum has been reported to be a region free of amyloid plaques in the AD brain. We obtained right and left standardized uptake value ratios as well as the corresponding means in each cerebral region.

**Statistical Analysis**

We described data separately in each PCA and AD group. Values were expressed as means ± SD or as frequency. Due to a skewed distribution and unequal variances, we used non-parametric tests for the analyses. We compared continuous data between the two groups using the Mann-Whitney test and gender ratios using the $\chi^2$ test. In PCA patients, we used Spearman rank correlations to detect associations between $^{18}$F-AV45 uptake and cognitive and affective symptoms or with CSF biomarker concentrations. Finally, we used the Wilcoxon signed-rank test to determine the binding symmetry in abnormal versus intact sides of regional $^{18}$F-AV45 uptake. All the tests were two-sided. The significance level was set at $p < 0.005$ and the statistical analyses were performed using R version 2.12.2 [46].

**Results**

**Characteristics of the Study Subjects**

We enrolled 11 patients with PCA (5 females and 6 males; aged 64.5 ± 7.3 years) and 12 patients with typical AD (6 females and 6 males; aged 69.3 ± 4.9 years). The demographic characteristics of the study sample are reported in Table 1. The two groups were similar with respect to age, gender distribution and disease duration. No significant differences were found between the two groups regarding levels of global cognitive efficiency (Mini-Mental State Examination), verbal and visual memory (Buschke Selective Reminding Test, 48-item Delayed Matching-to-Sample task) and naming (DO 80) (table 2).

All of the PCA patients presented focal atrophy or changes in perfusion (SPECT) in the posterior brain regions, which enhances the diagnostic probability. The clinical and biological...
findings of the 11 subjects with PCA are given in table 3. Six patients (patients 4, 5, 6, 7, 8 and 10) revealed associated neurological signs (myoclonus and/or extrapyramidal motor signs; Unified Parkinson’s Disease Rating Scale score >5). Seven PCA patients (patients 2, 4, 5, 7, 8, 10 and 11) had typical AD CSF biomarker profiles, and all had a decreased Aβ42/Aβ40 ratio.

PET Imaging

As reported in table 4, global and regional 18F-AV45 uptake was similar in the PCA and AD groups. The global 18F-AV45 uptake of each PCA and AD subject is presented in a boxplot (fig. 1). Examples of axial PET slices obtained for an AD and a PCA subject are shown in figure 2. Examples of axial SPECT and PET slices obtained for the same PCA subject are displayed in figure 3. Hypoperfusion was observed in the left parieto-occipital region, while no significant differences in 18F-AV45 uptake were detected between the right and left cerebral posterior regions.

No correlation was observed between the global 18F-AV45 uptake and the concentrations of CSF biomarkers (T-tau, p-tau, Aβ42 levels and Aβ42/Aβ40 ratio) and between the regional 18F-AV45 uptake and cognitive and affective symptoms in the PCA subjects.

No significant differences in the global 18F-AV45 uptake were found between PCA patients with or without associated neurological signs (1.51 ± 0.12 and 1.45 ± 0.15, respectively; p = 0.46) and between PCA patients with typical or atypical AD CSF biomarker profiles (1.49 ± 0.16 and 1.48 ± 0.09, respectively; p = 0.92).

In PCA subjects, no significant differences were observed between the corresponding right and left standardized uptake value ratios, in spite of the existence of an important later- alization of atrophy and/or hypoperfusion, in particular, in the occipital region.

Discussion

In this prospective study, we investigated the deposition of amyloid with 18F-AV45 in a cohort of 11 PCA patients who presented with either a typical or an atypical AD CSF profile. We then compared the density and topography of amyloid deposition between the PCA and AD patient groups.

In contrast to the neuropsychological signs, we found no specific regional pattern of cortical 18F-AV45 binding in the PCA group. The observed pattern was indistinguishable from that shown in the AD group, especially in the posterior regions. These results are in agreement

Table 2. Neuropsychological data of the PCA and AD groups

| Test                                      | PCA            | AD              | p value |
|-------------------------------------------|----------------|-----------------|---------|
| MMSE score (range 0–30)                   | 16.91 ± 6.66   | 20.64 ± 3.17a   | 0.356   |
| Buschke Selective Reminding Test          |                |                 |         |
| Free recall (range 0–48)                  | 5.67 ± 3.79b   | 6.62 ± 5.68c    | 1       |
| Total recall (range 0–48)                 | 25.33 ± 9.29b  | 18.62 ± 13.18c  | 0.3052  |
| % sensitivity (range 0–100)               | 45.67 ± 23.86b | 31.88 ± 25.88c  | 0.3063  |
| 48-Item Delayed Matching-to-Sample task   |                |                 |         |
| Immediate recall, %                       | 72.00 ± 10.35c | 71.43 ± 15.61d  | 0.9069  |
| Delayed recall, %                         | 71.75 ± 16.26c | 65.29 ± 17.09d  | 0.3833  |
| Oral naming (DO 80)                       | 68.56 ± 11.64c | 72.27 ± 4.36a   | 0.8185  |

a n = 11; b n = 3; c n = 8; d n = 7; e n = 9.
with previous $^{11}$C-PIB studies using a similar sample size [11, 21, 23] and with neuropathological studies, which suggests that PCA is mostly associated with underlying AD [4, 5]. This result confirms the pertinence of the new diagnostic criteria for AD, which distinguish amnestic AD presentations from non-amnestic clinical AD forms, such as those seen in patients who present with only visuospatial anomalies [47].

Similar to neuropathological studies, our results also confirm that the distinct clinical phenotype encountered in amnestic AD and PCA is not related to the amyloid distribution [22]. While this syndrome is defined by signs and symptoms of cortical visual dysfunction frequently associated with atrophy or hypoperfusion in the posterior cortical regions, we found similar patterns of $^{18}$F-AV45 binding between the PCA and AD groups. We also found no significant correlation between regional $^{18}$F-AV45 uptake and cognitive and affective symptoms in PCA subjects. Moreover, $^{18}$F-AV45 uptake was relatively symmetrical as opposed to the important lateralization of atrophy and/or hypoperfusion frequently observed in PCA patients, especially in the occipital region.

The distribution of the AD hallmarks seen in PCA varied in neuropathological studies, with some studies demonstrating a higher amyloid burden in the primary and associative visual cortex in PCA compared to typical amnestic AD [48, 49]. In contrast, previous studies

### Table 3. Clinical characteristics and CSF biomarker of PCA patients

| Patient No.: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
|--------------|---|---|---|---|---|---|---|---|---|----|----|
| Neurological examination | | | | | | | | | | | |
| Myoclonus | - | - | - | + | + | + | + | - | + | - |
| Extrapyramidal motor signs | 0 | 1 | 5 | 10 | 3 | 8 | 12 | 20 | 1 | 1 | 1 |
| Behavioural and affective symptoms | | | | | | | | | | | |
| Neuropsychiatric Inventory Scale (/144) | 6 | 5 | 6 | 27 | 1 | 41 | 22 | 21 | 19 | 18 | 38 |
| Hamilton Depression Rating Scale (/56) | 5 | 10 | 3 | 7 | 8 | 27 | 10 | 11 | 4 | 32 | 6 |
| CSF concentrations of biomarkers and amyloid-β ratios | | | | | | | | | | | |
| T-tau, pg/ml | 224 | 392 | 259 | 723 | 661 | 951 | 457 | 474 | 439 | 439 | 573 | 538 |
| p-tau, pg/ml | 43 | 62 | 56 | 96 | 103 | 92 | 83 | 67 | 54 | 76 | 86 |
| Aβ42, pg/ml | 276 | 300 | 305 | 346 | 277 | 756 | 281 | 388 | 460 | 632 | 340 |
| Aβ42/Aβ40 | 0.035 | 0.03 | 0.039 | 0.03 | ND | 0.058 | 0.02 | 0.03 | 0.042 | 0.04 | 0.03 |
| CSF profile (typical AD/atypical AD) | AT | T | AT | T | T | AT | T | T | AT | T | T |

UPDRS = Unified Parkinson’s Disease Rating Scale; AT = atypical; T = typical.

### Table 4. $^{18}$F-AV45 uptake of PCA and AD groups

| Neocortical $^{18}$F-AV45 uptake value | PCA (n = 11) | AD (n = 12) | p value |
|--------------------------------------|-------------|-------------|---------|
| Frontal | 1.67 ± 0.15 | 1.46 ± 0.20 | 0.0097 |
| Anterior cingulate | 1.67 ± 0.16 | 1.40 ± 0.20 | 0.0051 |
| Posterior cingulate | 1.32 ± 0.15 | 1.30 ± 0.13 | 0.7580 |
| Precuneus | 1.43 ± 0.14 | 1.35 ± 0.15 | 0.2297 |
| Temporal | 1.43 ± 0.14 | 1.35 ± 0.12 | 0.1653 |
| Parietal | 1.44 ± 0.16 | 1.43 ± 0.11 | 0.7345 |
| Occipital | 1.44 ± 0.12 | 1.41 ± 0.12 | 0.5380 |
| Global index | 1.49 ± 0.13 | 1.39 ± 0.12 | 0.0789 |

The significance level was set at p < 0.005.
**Fig. 1.** Comparison of the global standardized uptake value ratio (SUVR) index distributions between AD and PCA subjects.

**Fig. 2.** Example of axial PET slices obtained for an AD (a) and a PCA subject (b). No significant differences on the \textsuperscript{18}F-AV45 uptake are observed between AD and PCA subjects.

**Fig. 3.** Example of axial SPECT (a) and PET (b) slices obtained for the same PCA subject. Hypoperfusion is observed in the left parieto-occipital region while no significant differences on the \textsuperscript{18}F-AV45 uptake are observed between the right and left cerebral posterior regions.
did not report any differences in the distribution of Aβ pathologies [4, 5]. Amyloid imaging offers the opportunity of comparing in vivo neuropathological processes to the clinical symptoms. The results observed in neuropathological studies were confirmed by 11C-PIB PET studies [24]. Increased 11C-PIB uptake in the occipital cortex has been reported in single cases and studies [12, 17–19] containing small series, whereas larger-group studies have found no differences in 11C-PIB patterns between PCA and amnestic AD patients [11, 21, 23]. This study confirms that the amyloid burden cannot explain the differences in the clinical presentations of AD/PCA. Unlike amyloid deposition, a higher neurofibrillary tangle (NFT) burden is consistently seen in pathology studies [4, 5, 49] in PCA compared to AD, and in particular, a greater NFT density is observed in the primary visual and visual associative cortex. Clinicopathological studies have shown that NFT seems to be more closely related to clinical symptoms of AD than amyloid plaques [50, 51], but tracers with a specific affinity for NFT are still hard to find [52], and few have undergone any significant clinical development [53, 54].

We tried to determine whether the presence of neurological signs (extrapyramidal motor signs, myoclonus) was associated with differences in the density or topography of amyloid deposition in PCA patients. Indeed, some studies have suggested that the presence of an extrapyramidal syndrome or hallucinations at the onset of the disease may indicate that PCA is associated with Lewy body disease or corticobasal degenerative disease [5]. However, we failed to find any differences in 18F-AV45 binding when we compared PCA patients with or without associated neurological signs. This result suggests that the presence of associated neurological signs in PCA is not predictive of the underlying neuropathological process and indicates that biomarkers could be helpful to identify the underlying aetiology of PCA.

Few studies have investigated the combination of CSF biomarker analysis and amyloid imaging in PCA patients [11, 12]. None has analysed both the profile of CSF biomarkers (T-tau, p-tau and Aβ42) and the Aβ42/Aβ40 ratio [14], which is particularly interesting when an atypical CSF profile is present. In our study, a decreased Aβ42/Aβ40 ratio [14] was seen in all PCA patients including the 4 with atypical CSF profiles, thus confirming the amyloidogenic process. We found no differences in 18F-AV45 binding between PCA patients with a typical or atypical AD CSF profile. These results suggest that PCA patients with an atypical CSF profile do in fact have AD hallmarks just like patients with a typical AD CSF profile and no other neuropathological process like Lewy body disease or corticobasal degeneration disease. Moreover, we observed no correlation between global 18F-AV45 uptake and the concentrations of CSF biomarkers (T-tau, p-tau and Aβ42 levels, Aβ42/Aβ40 ratio). These results are not in accordance with previous studies conducted in typical AD patients [55] and warrant the standardization of CSF biomarkers in atypical AD presentations (PCA, primary progressive aphasia).

Our study has several limitations. First of all, the size of the study groups is small, but nonetheless comparable to the size of the study groups in other published series. Another limitation is the fact that we did not segment white and grey matter. Indeed, in these disease processes, we saw an increase in the amyloid burden in addition to its localization in the grey matter, which is considered specific. Since we did not apply a partial volume correction to the PET images, we chose to use the region of interest defined in the MNI-AAL atlas and incorporate both types of cerebral tissues. Another limitation is the fact that CSF biomarkers and brain perfusion with SPECT were not used in all AD subjects for their diagnosis. Finally, post-mortem verification would be helpful in order to confirm our findings, but this verification is obviously not possible.

The clinical criteria of PCA will thus continue to be the keystone for the diagnosis in clinical practice; however, in the future, confirmation of an AD pathology by 18F-AV45 PET imaging may provide an earlier diagnosis for PCA patients and consequently permit them to be included in therapeutic trials evaluating disease-modifying drugs and specific rehabili-
tation. Hypotheses other than amyloid deposition should be explored to try and explain the symptoms seen in the different clinical forms of AD. In light of the results of neuropathological studies, the implication of the tau pathology seems to be the most promising. Imaging studies using tracers with a specific affinity for NFT are needed in the future to help us gain a better understanding of atypical forms of AD.

Acknowledgments

This work was conducted with the support of the ‘Fondation Thérèse et René Planiol pour l'étude du cerveau’, Cyclopharma laboratories and the ‘Centre pour l'Etude et la Recherche sur les Radiopharmaceutiques’. The authors are also grateful to C. Roussel, PhD, S. Dupont (CIC-IT INSERM 0806), A. Matysiak, M. Brachet and F. Brault for their contributions to the clinical investigation.

References

1. Benson F, Davis J, Snyder BD: Posterior cortical atrophy. Arch Neurol 2011; 45: 789–793.
2. Crutch SJ, Schott JM, Rabinovici GD, Boeve BF, Cappa SF, Dickerson BC, Dubois B, Graff-Radford NR, Krolak-Salmon P, Lehmann M, Mendez MF, Pijnenburg Y, Ryan NS, Scheltens P, Shakespeare T, Tang-Wai DF, van der Flier WM, Bain L, Carrillo MC, Fox NC: Shining a light on posterior cortical atrophy. Alzheimers Dement 2013; 9: 463–465.
3. Kas A, de Souza LC, Samri D, Bartolomeo P, Lacomblez L, Kalafat M, Migliazzo R, Thiebaut de Schotten M, Cohen L, Dubois B, Habert MO, Sarazin M: Neural correlates of cognitive impairment in posterior cortical atrophy. Brain 2011; 134:1464–1478.
4. Renner JA, Burns JM, Hou CE, McKeel DW Jr, Storandt M, Morris JC: Progressive posterior cortical dysfunction: a clinicopathological series. Neurology 2004; 63:1175–1180.
5. Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, Caselli RJ, Knopman DS: Clinical, genetic, and neuropathological characteristics of posterior cortical atrophy. Neurology 2004;63:1168–1174.
6. Crutch SJ, Lehmann MS, Schott JM, Rabinovici GD, Rossor MN, Fox NC: Posterior cortical atrophy. Lancet Neurol 2012; 11:170–178.
7. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9:119–128.
8. Dubois B, Feldman HH, Jazova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Prioni G, Fox NC, Galasko D, Gauthier S, Jicha GA, Squirok K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P: Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118–1127.
9. Baumann TP, Duyar H, Sollberger M, Kuhle J, Regeniter A, Gomez-Mancilla B, Schmidtke K, Monsch AU: CSF-tau and CSF-Abeta(1–42) in posterior cortical atrophy. Dement Geriatr Cogn Disord 2010;29:530–533.
10. de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, Pe Darz, Dubois B, Sarazin M: Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. J Neurol Neurosurg Psychiatry 2010;82:240–246.
11. de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F, Chupin M, Lehéricy S, Colliot O, Hahn-Barma V, Samri D, Dubois B, Bottlaender M, Sarazin M: Similar amyloid-β burden in posterior cortical atrophy and Alzheimer’s disease. Brain 2011;134:2036–2043.
12. Formaglio M, Costes N, Seguin J, Tholance Y, Le Bars D, Rouillet-Solignac I, Mercier B, Krolak-Salmon P, Viggheto A: In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. J Neurol 2011;258:1841–1851.
13. Seguin J, Formaglio M, Perret-Liaudet A, Quadrio I, Tholance Y, Rouaud O, Thomas-Anterion C, Croisile B, Mollion H, Moreaud O, Salzmann M, Dorey A, Bataillard M, Coste MH, Viggheto A, Krolak-Salmon P: CSF biomarkers in posterior cortical atrophy. Neurology 2011;76:1782–1788.
14. Beaufils E, Dufour-Rainfray D, Hommet C, Brault F, Cottier JP, Ribeiro MJ, Mondon K, Guilloteau D: Confirmation of the amyloidigenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio. J Alzheimers Dis 2013;33:775–780.
15. Nordberg A: Amyloid imaging in Alzheimer’s disease. Curr Opin Neurol 2007; 20:398–402.
16. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitzcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Kivisto P, Antoni G, Mathis CA, Längström B: Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55: 306–319.
Ng SY, Villemagne VL, Masters CL, Rowe CC: Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol 2007; 64:1140–1144.

Tenovuo O, Kemppainen N, Aaltonen L, Nägren K, Rinne JO: Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis 2008; 15:351–355.

Kambe T, Motoi Y, Ishii K, Hattori N: Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex. J Neurol 2010; 257:469–471.

Migliaccio R, Agosta F, Rascovsky K, Karydas A, Bonasera S, Rabinovici GD, Miller BL, Gorno-Tempini ML: Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009; 73:1571–1578.

Rosenbloom MH, Alkalay A, Agarwal N, Baker SL, O’Neil JP, Janabi M, Yen IV, Growdon M, Jang J, Madison C, Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF: F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem 2005; 48:5980–5988.

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Miller BL, Jagust WJ, Rabinovici GD: Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011; 76:1789–1796.

Wolff DA, Price JC, Madeira C, Saxton JA, Snitz BE, Lopez OL, Mathis CA, K clinic WE, Dekosky ST: Amyloid imaging in dementias with atypical presentation. Alzheimers Dement 2012; 8:389–398.

Lehmann M, Ghosh PM, Madison C, Laforce FR Jr, Corbetta-Rastelli C, Weiner MW, Greidus MD, Seeley WW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD: Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer’s disease. Brain 2013; 136:844–858.

Wolff DA: Amyloid imaging in atypical presentations of Alzheimer’s disease. Curr Neurol Neurosci Rep 2013; 13:412.

Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF: F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem 2005; 48:5980–5988.

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasic J, Ye W, Hilton J, Lyketsos C, Kung HF, Yoshi AD, Skovronsky DM, Pontecorvo M: In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand [11C]-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010; 51:913–920.

Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, La Joie R, Tafani M, Hommet C, Chételat G, Mondon K, de La Sayette V, Cottier JP, Beaufils E, Ribeiro MJ, Gissot V, Vierrou E, Percoulie J, Vellas B, Eustache F, Guilloteau D: Using PET with [18F]-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012; 39:621–631.

Mendez MF, Ghajariana M, Perryman KM: Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer’s disease. Dement Geriatr Cogn Disord 2002; 13:44–40.

Rapport LJ, Mills SR, Bonello PJ: Validation of the Warrington theory of visual processing and the Visual Object and Space Perception Battery. J Clin Exp Neuropsychol 1998; 20:211–220.

Agniel A, Joanette Y, Doyon B, Duchein C: Protocole d’évaluation des gnosies visuelles. Isbergues, L’Orthoédie, 1992.

Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198.

Wechsler DA: Echelle d’intelligence de Wechsler pour adultes, forme révisée WAIS-R. Paris, Editions du Centre de Psychologie Appliquée, 1989.

Grober E, Buschke H: Genuine memory deficit in dementia. Dev Neuropsychol 1987; 3:13–36.

Van der Linden M, Coyette F, Poirenaud J, Kalafat M, Calcis F, Wym C, Adam S; les membres du GREMEM: L’épreuve de rappel libre/rappel indicé à 16 items; in Van der Linden M, les membres du GREMEM (eds): L’évaluation des troubles de la mémoire: Présentation de quatre tests de mémoire épidosique (avec leur étalonnage). Marseille, Solal, 2004.

Barbeau E, Tramoni E, Joubert S, Mancini J, Ceccaldi M, Ponchet M: Evaluation de la mémoire de reconnaissance visuelle: normalisation d’une nouvelle épreuve en choix forcéd (DMS48) et utilité en neuropsychologie clinique; in Van Der Linden M, les membres du GREMEM (eds): L’évaluation des troubles de la mémoire. Marseille, Solal, 2004, pp 85–101.

Deloche G, Hannequin D: Test de dénomination orale d’images DO 80. Paris, Editions du Centre de Psychologie Appliquée, 1997.

Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y: Evocation lexicale formelle et sémantique chez des sujets normaux. Performances et dynamiques de production en fonction du sexe, de l’âge et du niveau d’étude. Acta Neurol Belg 1990; 90:207–217.

Goodglass H, Kaplan E, Barresi B: The Assessment of Aphasia and Related Disorders, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2001.

Signoret JL: Evaluation des troubles de mémoire et des déficits cognitifs associés. B E C 96. Paris, IPSEN, 1988.

Mahieux-Laurent F, Fabre C, Galbrun E, Dubrulle A, Moroni C: groupe de réflexion sur les praxies du CMRR Ile-de-France Sud: Validation of a brief screening scale evaluating praxic abilities for use in memory clinics. Evaluation in 419 controls, 127 mild cognitive impairment and 320 demented patients. Rev Neurol 2009; 165: 560–567.

Cummings J, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308–2314.

Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62.
Beaufils et al.: The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using 18F-AV45: Is Amyloid the Principal Actor in the Disease?

43 McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–944.

44 Liu Y, Zhu L, Plössl K, Choi SR, Qiao H, Sun X, Li S, Zha Z, Kung HF: Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer’s disease. Nucl Med Biol 2010; 37: 917–925.

45 Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymond V, Ravert HT, Dannals RF, Nandi A, Brasic JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ: In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med 2010; 51: 913–920.

46 Development Core Team: A Language and Environment for Statistical Computing. Vienna, Foundation for Statistical Computing, 2011. http://www.R-project.org/.

47 McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koreschetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 2011; 7: 263–269.

48 Von Gunten A, Bouras C, Kovari E, Giannakopoulos P, Hof PR: Neural substrates of cognitive and behavioural deficits in atypical Alzheimer’s disease. Brain Res Rev 2006; 51: 176–211.

49 Hof PR, Vogt BA, Bouras C, Morrison JH: Atypical form of Alzheimer’s disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res 1997; 37: 3609–3625.

50 Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992; 42: 631–639.

51 Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 1997; 41: 17–24.

52 Tauber C, Beaufils E, Hommet C, Ribeiro MJ, Vercouillie J, Vierron E, Mondon K, Cotton JP, Gassot V, Guilloteau D, Camus V: Brain [18F]FDG binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer’s disease patients. J Alzheimers Dis 2013; 36: 311–320.

53 Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharan U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Modcharla VP, Mu F, Sinha A, Szardenings AK, Wang E, Walsh JC, Xia C, Yu C, Zhao T, Kolb HC: A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 2012; 31: 601–612.

54 Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC: Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2012; 34: 457–468.

55 Landau SM, Lu M, Yoshi AD, Pontecorvo M, Mintun MA, Trpanowski JQ, Shaw LM, Jagust WJ: Alzheimer’s Disease Neuroimaging Initiative: Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurrol 2013; 74: 826–836.